Interesting to see where Bell Potters Price Target increases to givenOn December 20, Bell Potter raised its target for Mesoblast to $3.90 from $1.40 following FDA approval of Ryoncil for treating steroid-refractory acute graft-versus-host disease (SR-aGvHD) in paediatric patients aged two months and older.
The broker's revenue forecast was based on a
- base price of US$750,000 per patient
- a market of fewer than 200 patients annually.
Anyone a subscriber?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.005(0.31%) |
Mkt cap ! $2.063B | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.66 | $1.60 | $4.602M | 2.818M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 70944 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.61 | 29909 | 35 |
View Market Depth
| Last trade - 14.19pm 26/06/2025 (20 minute delay) ? |
| MSB (ASX) Chart |